PetMed Express (PETS) Set to Post Quarterly Earnings on Tuesday

PetMed Express (NASDAQ:PETS) is expected to post its Q2 2027 results after the market closes on Tuesday, November 10th. Analysts expect PetMed Express to announce earnings of ($0.11) per share and revenue of $62.00 million for the quarter. Interested persons can check the company’s upcoming Q2 2027 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

PetMed Express (NASDAQ:PETS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.40). The firm had revenue of $41.02 million during the quarter, compared to analysts’ expectations of $71.00 million. PetMed Express had a negative net margin of 17.34% and a negative return on equity of 91.69%. On average, analysts expect PetMed Express to post ($0.50) EPS for the current fiscal year and ($0.35) EPS for the next fiscal year.

PetMed Express Trading Down 0.4%

Shares of NASDAQ:PETS traded down $0.01 during midday trading on Tuesday, hitting $1.20. 5,082 shares of the stock were exchanged, compared to its average volume of 282,240. PetMed Express has a twelve month low of $1.15 and a twelve month high of $4.10. The company has a 50 day moving average price of $1.47 and a 200-day moving average price of $2.11. The stock has a market cap of $25.91 million, a P/E ratio of -0.87 and a beta of 0.82.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on PETS shares. Weiss Ratings raised shares of PetMed Express from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 14th. Zacks Research lowered PetMed Express from a “hold” rating to a “strong sell” rating in a research note on Friday, September 25th. Morgan Stanley lowered their target price on PetMed Express from $2.15 to $1.40 and set an “underweight” rating on the stock in a report on Friday, September 25th. Finally, Wall Street Zen downgraded PetMed Express from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three analysts have rated the stock with a Sell rating. According to data from MarketBeat.com, PetMed Express presently has an average rating of “Strong Sell” and a consensus target price of $1.40.

About PetMed Express

PetMed Express, Inc, doing business as PetMeds, is an online retailer of prescription and nonprescription medications and health products for dogs, cats and other household pets. The company offers products used to treat or prevent conditions such as allergies, infections, parasites and chronic illnesses, including prescription medicines, flea and tick treatments, heartworm preventatives, supplements and other animal-health products.

In addition to medications, PetMeds sells pet food, treats, vitamins, wellness products and selected supplies.